Zacks Research Issues Optimistic Estimate for FOLD Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for Amicus Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their prior forecast of $0.04. The consensus estimate for Amicus Therapeutics’ current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.36 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $0.56 EPS.

Other research analysts also recently issued research reports about the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Price Performance

FOLD opened at $7.95 on Wednesday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a market capitalization of $2.44 billion, a P/E ratio of -44.17, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company’s 50 day simple moving average is $9.22 and its 200-day simple moving average is $9.91. Amicus Therapeutics has a one year low of $7.76 and a one year high of $12.65.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of FOLD. Vanguard Group Inc. raised its holdings in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock worth $275,619,000 after purchasing an additional 458,143 shares during the period. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after buying an additional 4,497,950 shares in the last quarter. Geode Capital Management LLC raised its stake in Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock worth $70,499,000 after buying an additional 80,926 shares during the period. Nuveen Asset Management LLC lifted its holdings in Amicus Therapeutics by 4.4% during the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after acquiring an additional 159,139 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock valued at $31,761,000 after acquiring an additional 187,652 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.